EA032000B1 - Способы лечения демиелинизирующей периферической нейропатии, вызванной травмой - Google Patents

Способы лечения демиелинизирующей периферической нейропатии, вызванной травмой Download PDF

Info

Publication number
EA032000B1
EA032000B1 EA201400966A EA201400966A EA032000B1 EA 032000 B1 EA032000 B1 EA 032000B1 EA 201400966 A EA201400966 A EA 201400966A EA 201400966 A EA201400966 A EA 201400966A EA 032000 B1 EA032000 B1 EA 032000B1
Authority
EA
Eurasian Patent Office
Prior art keywords
ivig
cells
patient
nerve
body weight
Prior art date
Application number
EA201400966A
Other languages
English (en)
Russian (ru)
Other versions
EA201400966A1 (ru
Inventor
Патрик Кюри
Невена Цекова
Ханс-Петер Хартунг
Коринна Херманн
Биргит Мария Райперт
Ханс-Петер Шварц
Хартмут Эрлих
Зебастьян Бунк
Original Assignee
Баксалта Инкорпорейтид
Баксалта Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Баксалта Инкорпорейтид, Баксалта Гмбх filed Critical Баксалта Инкорпорейтид
Publication of EA201400966A1 publication Critical patent/EA201400966A1/ru
Publication of EA032000B1 publication Critical patent/EA032000B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
EA201400966A 2012-02-29 2013-02-28 Способы лечения демиелинизирующей периферической нейропатии, вызванной травмой EA032000B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605117P 2012-02-29 2012-02-29
PCT/US2013/028350 WO2013130826A2 (en) 2012-02-29 2013-02-28 Igg stimulated remyelination of peripheral nerves

Publications (2)

Publication Number Publication Date
EA201400966A1 EA201400966A1 (ru) 2014-12-30
EA032000B1 true EA032000B1 (ru) 2019-03-29

Family

ID=47884569

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201400966A EA032000B1 (ru) 2012-02-29 2013-02-28 Способы лечения демиелинизирующей периферической нейропатии, вызванной травмой
EA201892521A EA201892521A1 (ru) 2012-02-29 2013-02-28 РЕМИЕЛИНИЗАЦИЯ ПЕРИФЕРИЧЕСКИХ НЕРВОВ, СТИМУЛИРОВАННАЯ IgG

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201892521A EA201892521A1 (ru) 2012-02-29 2013-02-28 РЕМИЕЛИНИЗАЦИЯ ПЕРИФЕРИЧЕСКИХ НЕРВОВ, СТИМУЛИРОВАННАЯ IgG

Country Status (21)

Country Link
US (5) US8986670B2 (enExample)
EP (2) EP2820042B1 (enExample)
JP (3) JP6335800B2 (enExample)
KR (3) KR20200126005A (enExample)
CN (4) CN107551269A (enExample)
AR (2) AR090211A1 (enExample)
AU (3) AU2013203088B2 (enExample)
BR (1) BR112014021240A2 (enExample)
DK (2) DK2820042T3 (enExample)
EA (2) EA032000B1 (enExample)
ES (2) ES2755056T3 (enExample)
FI (1) FI3590960T3 (enExample)
HK (1) HK1248534A1 (enExample)
IL (3) IL277103B2 (enExample)
MX (2) MX369444B (enExample)
NZ (1) NZ629867A (enExample)
PL (2) PL3590960T3 (enExample)
PT (2) PT3590960T (enExample)
SG (1) SG11201405302WA (enExample)
TW (3) TW201838654A (enExample)
WO (1) WO2013130826A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2820042T3 (da) * 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11511136B2 (en) 2017-11-17 2022-11-29 The Research Foundation For The State University Of New York Method for treating damaged peripheral nerves using x-ray microbeam irradiation
US20220111012A1 (en) * 2019-01-07 2022-04-14 Mallinckrodt Ard Ip Unlimited Company Methods of promoting remyelination
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
EP4737584A1 (en) * 2023-06-30 2026-05-06 FUJIFILM Corporation Method for evaluating intercellular interaction of neuroinflammation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
AT376367B (de) 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3473407D1 (en) 1983-05-02 1988-09-22 Immuno Ag Method of inactivating pathogens
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
WO1992003536A1 (en) * 1990-08-15 1992-03-05 University Of Miami And Its School Of Medicine Autotransplantation of schwann cells to promote nervous system repair
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
JP3133338B2 (ja) 1992-12-16 2001-02-05 イムノ・アクチエンゲゼルシャフト ウイルス的に安全な生物学的組成物の調製方法
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
HRP940645A2 (en) 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
IL140155A (en) 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
EP2287191B1 (en) * 2000-05-10 2016-10-12 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP2003070465A (ja) * 2001-08-31 2003-03-11 Keio Gijuku シュワン細胞の培養方法
UY28170A1 (es) 2003-01-24 2004-07-30 Elan Pharm Inc Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
MXPA06008435A (es) * 2004-01-30 2007-05-23 Suomen Punainen Risti Veripalvelu Proceso de manufactura de una inmunoglobulina libre de virus.
ES2407380T5 (es) 2004-02-27 2017-07-07 Octapharma Ag Procedimiento para proporcionar una preparación de anticuerpos purificada, sin riesgo respecto a virus
NZ578816A (en) * 2007-02-02 2012-06-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
US7854703B2 (en) 2007-09-25 2010-12-21 Intel Corporation Peripheral neuropathy detection
CA2643496C (en) 2008-11-06 2015-02-03 Michael Fehlings The therapeutic use of igg as a neuroprotective agent
CN102021140B (zh) * 2009-09-18 2013-04-24 上海市第一人民医院 一种分离、纯化许旺细胞的方法
DK2820042T3 (da) * 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
COLOVER, J.: "Polyneuropathy in type 2 diabetes mellitus", LANCET, ELSEVIER, AMSTERDAM, NL, vol. 358, no. 9298, 15 December 2001 (2001-12-15), AMSTERDAM, NL, pages 2086, XP004805732, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(01)07124-0 *
ENGLAND, J.D. ASBURY, A.K.: "Peripheral neuropathy", LANCET, ELSEVIER, AMSTERDAM, NL, vol. 363, no. 9427, 26 June 2004 (2004-06-26), AMSTERDAM, NL, pages 2151 - 2161, XP004778376, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(04)16508-2 *
HONMOU O, ET AL.: "RESTORATION OF NORMAL CONDUCTION PROPERTIES IN DEMYELINATED SPINAL CORD AXONS IN THE ADULT RAT BY TRANSPLANTATION OF EXOGENOUS SCHWANNCELLS", THE JOURNAL OF NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, US, vol. 16, no. 10, 15 May 1996 (1996-05-15), US, pages 3199 - 3208, XP002945997, ISSN: 0270-6474 *
JOERG-PATRICK STÜBGEN;: "Drug-induced dysimmune demyelinating neuropathies", JOURNAL OF NEUROLOGICAL SCIENCES., ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM., NL, vol. 307, no. 1, 11 May 2011 (2011-05-11), NL, pages 1 - 8, XP028234970, ISSN: 0022-510X, DOI: 10.1016/j.jns.2011.05.010 *
KRENDEL DAVID A; COSTIGAN DONAL A; HOPKINS LINTON C: "Successful treatment of neuropathies in patients with diabetes mellitus", ARCHIVES OF NEUROLOGY., AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, vol. 52, no. 11, 1 November 1995 (1995-11-01), US, pages 1053 - 1061, XP008161377, ISSN: 0003-9942, DOI: 10.1001/archneur.1995.00540350039015 *
KUHLMANN T, WENDLING U, NOLTE C, ZIPP F, MARUSCHAK B, STADELMANN C, SIEBERT H, BRÜCK W.: "Differential regulation of myelin phagocytosis by macrophages/microglia, involvement of target myelin, Fc receptors and activation by intravenous immunoglobulins", JOURNAL OF NEUROSCIENCE RESEARCH., WILEY-LISS., US, vol. 67, no. 2, 15 January 2002 (2002-01-15), US, pages 185 - 190, XP002706323, ISSN: 0360-4012, DOI: 10.1002/jnr.10104 *
N. LATOV , JOHN H. J. WOKKE , JOHN J. KELLY , BYRON WAKSMAN: "Immunological and infectious diseases of the peripheral nerves", 28 May 1998, CAMBRIDGE UNIV. PRESS, Cambridge, ISBN: 978-0-521-46265-5, article "Immunology and infectious diseases of the peripheral nerves , passage", pages: 340 - 340, XP002706321 *
NOTGHI, L.M. ; WRIGHT, S. ; QUINLIVAN, R.: "P12-12 Neonatal axonal neuropathy: a curious presentation of congenital hypomyelination", CLINICAL NEUROPHYSIOLOGY, ELSEVIER SCIENCE,, IE, vol. 121, 1 October 2010 (2010-10-01), IE, pages S174 - S175, XP027454865, ISSN: 1388-2457, DOI: 10.1016/S1388-2457(10)60716-X *
ODAKA M, ET AL: "Treatment response to steroid and intravenous immunoglobulin in a patient with chronic sensory demyelinating neuropathy", JOURNAL OF CLINICAL NEUROMUSCULAR DISEASE, LIPPINCOTT WILLIAMS & WILKINS, HAGERSTOWN, MD, US, vol. 8, no. 4, 1 June 2007 (2007-06-01), US, pages 207 - 211, XP002695284, ISSN: 1522-0443, DOI: 10.1097/CND.0b013e318070bfeb *
SEKIGUCHI, K. ; KANDA, F. ; TODA, T. ; KOHARA, N.: "P12-11 Nerve conduction characteristics of infliximab induced demyelinating neuropathy", CLINICAL NEUROPHYSIOLOGY, ELSEVIER SCIENCE,, IE, vol. 121, 1 October 2010 (2010-10-01), IE, pages S174, XP027454864, ISSN: 1388-2457, DOI: 10.1016/S1388-2457(10)60715-8 *
STANGEL M: "[Transplantation of myelinating cells as regenerative therapy for multiple sclerosis: Experimental basis and present state of clinical studies.]", NERVENARZT., SPRINGER VERLAG, BERLIN., DE, vol. 73, no. 10, 1 October 2002 (2002-10-01), DE, pages 937 - 945, XP002706322, ISSN: 0028-2804, DOI: 10.1007/s00115-002-1370-8 *
VAN SCHAIK I N; VERMEULEN M; BRAND A: "Immunomodulation and remyelination: two aspects of human polyclonal immunoglobulin treatment in immune mediated neuropathies?", MULTIPLE SCLEROSIS JOURNAL (MSJ), SAGE PUBLICATIONS, BASINGSTOKE, GB, vol. 3, no. 2, 1 April 1997 (1997-04-01), BASINGSTOKE, GB, pages 98 - 104, XP008161364, ISSN: 1352-4585, DOI: 10.1177/135245859700300208 *
VARGAS M E, WATANABE J, SINGH S J, ROBINSON W H, BARRES B A: "Endogenous antibodies promote rapid myelin clearance and effective axon regeneration after nerve injury", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, NATIONAL ACADEMY OF SCIENCES, US, vol. 107, no. 26, 29 June 2010 (2010-06-29), US, pages 11993 - 11998, XP002695282, ISSN: 0027-8424, DOI: 10.1073/pnas.1001948107 *
VERMA A; BRADLEY W G: "High-dose intravenous immunoglobulin therapy in chronic progressive lumbosacral plexopathy.", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 44, no. 2, 1 February 1994 (1994-02-01), US, pages 248 - 250, XP008163795, ISSN: 0028-3878, DOI: 10.1212/WNL.44.2.248 *
WARRINGTON A E, ET AL.: "HUMAN MONOCLONAL ANTIBODIES REACTIVE TO OLIGODENDROCYTES PROMOTE REMYELINATION IN A MODEL OF MULTIPLE SCLEROSIS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, NATIONAL ACADEMY OF SCIENCES, US, vol. 97, no. 12, 6 June 2000 (2000-06-06), US, pages 6820 - 6825, XP000941806, ISSN: 0027-8424, DOI: 10.1073/pnas.97.12.6820 *
ZHANG, J. ; O'CARROLL, S.J. ; WU, A. ; NICHOLSON, L.F.B. ; GREEN, C.R.: "A model for ex vivo spinal cord segment culture-A tool for analysis of injury repair strategies", JOURNAL OF NEUROSCIENCE METHODS., ELSEVIER SCIENCE PUBLISHER B.V., AMSTERDAM., NL, vol. 192, no. 1, 30 September 2010 (2010-09-30), NL, pages 49 - 57, XP027258913, ISSN: 0165-0270 *
ZOCHODNE DW, ISAAC D, JONES C.: "Failure of immunotherapy to prevent, arrest or reverse diabetic lumbosacral plexopathy", ACTA NEUROLOGICA SCANDINAVICA., MUNKSGAARD, COPENHAGEN., DK, vol. 107, no. 4, 1 April 2003 (2003-04-01), DK, pages 299 - 301, XP002695283, ISSN: 0001-6314, DOI: 10.1034/j.1600-0404.2003.02107.x *

Also Published As

Publication number Publication date
MX2019012496A (es) 2020-01-20
AU2016201137A1 (en) 2016-03-10
US10494418B2 (en) 2019-12-03
TW201400502A (zh) 2014-01-01
HK1206035A1 (en) 2015-12-31
PL2820042T3 (pl) 2020-03-31
EP2820042A2 (en) 2015-01-07
NZ629867A (en) 2016-09-30
EA201892521A1 (ru) 2019-07-31
AU2016201137B2 (en) 2017-10-12
IL234303B (en) 2020-09-30
IL277103A (en) 2020-10-29
DK3590960T3 (da) 2023-04-24
WO2013130826A2 (en) 2013-09-06
TWI700297B (zh) 2020-08-01
JP2020059705A (ja) 2020-04-16
CN109966488A (zh) 2019-07-05
CN104302666A (zh) 2015-01-21
SG11201405302WA (en) 2014-09-26
PL3590960T3 (pl) 2023-07-17
IL277103B1 (en) 2025-03-01
CN110343171A (zh) 2019-10-18
US20180291087A1 (en) 2018-10-11
ES2943585T3 (es) 2023-06-14
PT3590960T (pt) 2023-04-18
AU2018200026A1 (en) 2018-01-25
AR117207A2 (es) 2021-07-21
PT2820042T (pt) 2019-10-31
MX369444B (es) 2019-11-08
AU2013203088B2 (en) 2015-12-03
TWI632158B (zh) 2018-08-11
JP2015508824A (ja) 2015-03-23
EP3590960A1 (en) 2020-01-08
KR20200126005A (ko) 2020-11-05
FI3590960T3 (fi) 2023-04-25
DK2820042T3 (da) 2019-10-28
WO2013130826A3 (en) 2013-12-05
US8986670B2 (en) 2015-03-24
EA201400966A1 (ru) 2014-12-30
AR090211A1 (es) 2014-10-29
AU2018200026B2 (en) 2019-12-05
CN107551269A (zh) 2018-01-09
KR102673154B1 (ko) 2024-06-05
TW201736398A (zh) 2017-10-16
AU2013203088A1 (en) 2013-09-19
IL274512A (en) 2020-06-30
US9834593B2 (en) 2017-12-05
ES2755056T3 (es) 2020-04-21
IL277103B2 (en) 2025-07-01
EP2820042B1 (en) 2019-07-24
KR102170615B1 (ko) 2020-10-28
HK1248534A1 (zh) 2018-10-19
US20200216518A1 (en) 2020-07-09
KR20140134690A (ko) 2014-11-24
US20150232536A1 (en) 2015-08-20
US20130224150A1 (en) 2013-08-29
IL274512B2 (en) 2024-07-01
KR20220045087A (ko) 2022-04-12
TW201838654A (zh) 2018-11-01
EP3590960B1 (en) 2023-03-29
MX2014010387A (es) 2015-09-25
US20210300997A1 (en) 2021-09-30
IL274512B1 (en) 2024-03-01
JP6335800B2 (ja) 2018-05-30
BR112014021240A2 (pt) 2018-09-18
JP6979990B2 (ja) 2021-12-15
JP2018030856A (ja) 2018-03-01
JP6637934B2 (ja) 2020-01-29

Similar Documents

Publication Publication Date Title
JP6979990B2 (ja) 末梢神経のＩｇＧ刺激性再ミエリン化法
HK40018190B (en) Igg stimulated remyelination of peripheral nerves
EA040995B1 (ru) Ремиелинизация периферических нервов, стимулированная igg
HK40018190A (en) Igg stimulated remyelination of peripheral nerves
RU2844863C1 (ru) Применение молекул, связывающих семафорин-4d, для лечения синдрома ретта
Sonoda et al. Neutrophil‐dominant experimental autoimmune uveitis in CC‐chemokine receptor 2 knockout mice
JP7748728B2 (ja) 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用
HK1206035B (en) Igg stimulated remyelination of peripheral nerves

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KG TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM